# FX-909

Source: https://onco.cc/drugs/fx-909/  
OnCo record `fx-909` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

FX-909 is an experimental pill from Flare Therapeutics, in phase 1 trials for advanced urothelial (bladder) cancer.

## Summary

FX-909 is a small molecule, oral from Flare Therapeutics. Blocks PPARG, a transcription factor that the company describes as the master regulator of the luminal lineage of bladder cancer cells. The phase 1 study NCT05929235 tests it alone and with pembrolizumab; the company describes a randomised phase 1b part in PPARG-high locally advanced or metastatic urothelial cancer after earlier treatment. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: FX-909
- Modality: Small molecule, oral
- Mechanism: Blocks PPARG, a transcription factor that the company describes as the master regulator of the luminal lineage of bladder cancer cells.

## Sources

- Flare Therapeutics FX-909: https://www.flaretx.com/fx-909/
- ClinicalTrials.gov NCT05929235: https://clinicaltrials.gov/study/NCT05929235

## Connected records

- cancers: [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/)
- targets: [PPARG](https://onco.cc/targets/pparg/)
- companies: [Flare Therapeutics](https://onco.cc/companies/flare-therapeutics/)
- trials: [A Study of FX-909 in Patients With Advanced Solid Malignancies, Including Advanced Urothelial Carcinoma](https://onco.cc/trials/nct05929235/)

---
JSON: https://onco.cc/api/v1/entities/fx-909.json